Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: A national review by the Canadian Blood and Marrow Transplant Group

Bone Marrow Transplantation

Volumn 45, Issue 7, 2010, Pages 1253-1255

  Kuruvilla, J ^a   Pintilie, M ^a   Stewart, D ^a   Lachance, S ^a   Power, M ^a   Couture, F ^a   Xenocostas, A ^a   Voralia, M ^a   Couban, S ^a   Foley, R ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LETTER; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; CANADA; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PROCEDURES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CANADA; HODGKIN DISEASE; HUMANS; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955012456     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.321     Document Type: Letter

References (9)

1. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678.
2. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 2004; 34: 511-514.
3. Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007; 139: 70-80.
4. Lauri MB, Paul VOD, Brenda MS, Barry ES, Leo L, Heather JS et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin's lymphoma. Biol Blood and Marrow Transplant 2008; 14: 1279-1287.
5. Marcel PD, Parameswaran NH, Jeanette C, Brent RL, Koen van B, Christopher NB et al. Unrelated donor reducedintensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood and Marrow Transplant 2009; 15: 109-117.
6. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the lymphoma working party of the european group for blood and marrow transplantation. J Clin Oncol 2008; 26: 455-462.
7. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369.
8. Crump M. Management of Hodgkin's lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program 2008, 326-333.
9. Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41: 765-770.